GT Biopharma (NASDAQ:GTBP) reported quarterly losses of $(0.10) per share. This is a 33.33 percent increase over losses of $(0.15) per share from the same period last year.
PolyPid Announces Top-line Results Of Phase 3 SHIELD I Trial Of D-PLEX100 Did Not Achieve Its Primary Endpoint For The Prevention Of Surgical Site Infections In Abdominal Surgery
SHIELD I Study did not Achieve its Primary Endpoint of Reduction in Surgical Site Infections and Mortality
In an FDA Requested Pre-specified Subgroup Analysis in Subjects with Incision Lengths over 20 centimeters
